Showing results (61-70 of 66) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Scientific Reports|January 20, 2018
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and OnchocerciasisGhaith Aljayyoussi, Hayley E Tyrer, Louise Ford, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 19, 2016
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung CancerHui Yu, Cory Batenchuk, Andrzej Badzio, et al.The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2017
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, David R Spigel, Everett E Vokes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerHossein Borghaei, Scott Gettinger, Everett E Vokes, et al.Lancet (London, England)|February 10, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS<sup>G12C</sup> mutation: a randomised, open-label, phase 3 trialAdrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, et al.Pageof 7